Dr. O'Shaughnessy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1809
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
- Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1985
- Yale School of MedicineClass of 1982
Certifications & Licensure
- TX State Medical License 1997 - 2026
- IN State Medical License 1995 - 1999
- KY State Medical License 1995 - 1999
- MD State Medical License 1985 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Clinical Trials
- PhII ICb With/Without Erbitux in MBC Pts Start of enrollment: 2005 Jul 28
- Satraplatin for Patients With Metastatic Breast Cancer (MBC) Start of enrollment: 2005 Nov 01
- A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1310 citationsPembrolizumab for Early Triple-Negative Breast Cancer.Peter Schmid, Javier Cortes, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel
The New England Journal of Medicine. 2020-02-26 - 60 citationsHybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancerJon Chung, Dean Pavlick, Ryan J. Hartmaier, Alexa B. Schrock, Lauren Young
Annals of Oncology. 2017-11-01 - 486 citationsExtending Survival with Chemotherapy in Metastatic Breast CancerJoyce A. O'Shaughnessy
The Oncologist. 2005-10-01
Lectures
- CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone...2019 ASCO Annual Meeting - 6/1/2019
- First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 lo...2019 ASCO Annual Meeting - 6/1/2019
- Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
- What Is Inflammatory Breast Cancer? Patient Jennifer Cordts Talks with Dr. Joyce O’ShaughnessyFebruary 28th, 2023
- Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCSJanuary 24th, 2023
- Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast CancerOctober 20th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: